| Company Name: |
Chembest Research Laboratories Limited
|
| Tel: |
+86-21-20908456 |
| Email: |
sales@BioChemBest.com |
| Products Intro: |
Product Name:(+)-Apogossypol
CAS:66389-74-0
Purity:98% HPLC Package:10mg;50mg;100mg;500mg;1g Remarks:Biochemical Reagents; Pharmaceutical Intermediates
|
apogossypol manufacturers
- (+)-Apogossypol
-
- $3100.00 / 100mg
-
2025-08-22
- CAS:66389-74-0
- Min. Order:
- Purity:
- Supply Ability: 10g
- apogossypol
-
- $0.00 / 1kg
-
2025-04-04
- CAS:66389-74-0
- Min. Order: 1kg
- Purity: 98%
- Supply Ability: 1Ton
- (+)-Apogossypol
-
- $3100.00 / 100mg
-
2024-10-24
- CAS:66389-74-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | apogossypol Basic information |
| Product Name: | apogossypol | | Synonyms: | apogossypol;(+)-3,3'-Dimethyl-5,5'-bis(1-methylethyl)-2,2'-binaphthalene-1,1',6,6',7,7'-hexol;NSC736630;APOGOSSYPOL;NSC736630;3-methyl-5-propan-2-yl-2-(1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)naphthalene-1,6,7-triol;(+)-APOGOSSYPOL;[2,2'-Binaphthalene]-1,1',6,6',7,7'-hexol, 3,3'-dimethyl-5,5'-bis(1-methylethyl)-, (2S)-;(+)Apogossypol,(+) Apogossypol | | CAS: | 66389-74-0 | | MF: | C28H30O6 | | MW: | 462.53 | | EINECS: | | | Product Categories: | | | Mol File: | 66389-74-0.mol |  |
| | apogossypol Chemical Properties |
| Melting point | 118-123 °C | | Boiling point | 673.3±50.0 °C(Predicted) | | density | 1.335±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | >16.2mg/mL in DMSO with gentle warming | | form | Powder | | pka | 8.03±0.50(Predicted) |
| | apogossypol Usage And Synthesis |
| Uses | (+)-Apogossypol is a pan-BCL-2 antagonist. (+)-Apogossypol binds to Mcl-1, Bcl-2 and Bcl-xL with EC50s of 2.6, 2.8 and 3.69 μM, respectively. | | Biological Activity | (+)-Apogossypol is a pan-BCL-2 antagonist that binds to Mcl-1, Bcl-2 and Bcl-xL with EC50 of 2.6, 2.8 and 3.69 μM, respectively. | | in vitro | In agreement with NMR binding and fluorescence polarization assays (FPAs) data, (+)-Apogossypol displays potent binding affinity to Bcl-xL with K d values of 1.7 μM. | | in vivo | Due to its modified structure, (+)-Apogossypol is expected to exhibit lower toxicity while maintaining the significant anti-growth and anti-tumor activities in vitro, similar to those of Gossypol. | | target | | Mcl-1 < span> 2.6 μM (EC 50 ) | Bcl-2 2.8 μM (EC 50 ) | Bcl-xL 3.69 μM (EC 50 ) | | | IC 50 | Mcl-1: 2.6 μM (EC50); Bcl-2: 2.8 μM (EC50); Bcl-xL: 3.69 μM (EC50) | | References | [1] Wei J, et al. Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2009 Apr;8(4):904-13. DOI:10.1158/1535-7163.MCT-08-1050
[2] Zhan W, et al. Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo. Mol Med Rep. 2015 Jun;11(6):4142-8. DOI:10.3892/mmr.2015.3326 |
| | apogossypol Preparation Products And Raw materials |
|